Stay updated on Sitravatinib Combo vs Docetaxel in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Sitravatinib Combo vs Docetaxel in Lung Cancer Clinical Trial page.

Latest updates to the Sitravatinib Combo vs Docetaxel in Lung Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check18 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed study information regarding the efficacy of sitravatinib in combination with nivolumab for treating advanced non-squamous non-small cell lung cancer, and the addition of a new revision identifier.SummaryDifference6%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe page has been updated to reflect an increase in the number of study locations from 246 to 261, and several local institutions have been added, including new locations in Naples and Dickson, Tennessee. Additionally, multiple institutions have been removed, including notable cancer centers across various states.SummaryDifference32%
- Check77 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.6%
- Check92 days agoChange DetectedThe website has updated to revision v2.14.2, noting that some NLM-NCBI services are experiencing heavy traffic, which may impact performance and availability.SummaryDifference0.6%
- Check107 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.0%
Stay in the know with updates to Sitravatinib Combo vs Docetaxel in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sitravatinib Combo vs Docetaxel in Lung Cancer Clinical Trial page.